Despite the COVID-19 crisis, the Indian Pharmaceutical market registered a surprising growth of 8.9% in Mar’20 with some evidence of panic buying in Chronic Medicines as reported by AIOCD AWACS.
Corporates exhibiting above industry growth (8.9%) for Mar-20 as per Rank Bucket are, Intas Pharma, Mankind Pharma, Aristo Pharma, Dr. Reddy's Lab, Boehringer, Corona Remedies, Leeford, Danone, Alniche, Unison Pharma and Indiabulls Pharmaceuticals. Out of which, Intas Pharma and Mankind Pharma are top performers.
Cardiac registered a monthly growth of 19.8% compared to 11.0% in Feb'20, Anti-Diabetic registered growth of 18.2% compared to 11.0% in Feb'20 and Respiratory medicines grew at 22.9% compared to 11.5% in Feb'20.
Considering the lock down period for one week plus in Mar'20, there was struggle for Gastro 6.4%, Vitamins 3.7%, Pain & Analgesics 4.8% and Derma -1.7%.
Also, it is noted that many pharmaceuticals including Sun Pharma, Cipla, Zydus Cadila exhibit high gain in stock market. Surge in demand of hydroxychloroquine will also be important factor for future growth of pharmaceutical industries in the country.
